In this study, we also provide evidence that SOX2 desensitizes melanoma cells to BRAF inhibition, likely by decreasing intracellular drug accumulation through transcriptional activation of the ABCG2/BCRP drug efflux transporter. This evidence concerns the gene SOX2 and melanoma.